Medicine & Life Sciences
Non-Small Cell Lung Carcinoma
100%
Clinical Trials
87%
Neoplasms
63%
Lung Neoplasms
52%
Survival
51%
Biomarkers
40%
Progression-Free Survival
39%
Therapeutics
38%
Small Cell Lung Carcinoma
29%
Response Evaluation Criteria in Solid Tumors
26%
Drug Therapy
25%
Bortezomib
22%
Acute Myeloid Leukemia
21%
PCI 32765
21%
Sulindac
21%
Multiple Myeloma
20%
Placebos
20%
Carboplatin
19%
Genotype
19%
midostaurin
19%
Pemetrexed
18%
Chemoprevention
18%
National Cancer Institute (U.S.)
18%
Maximum Tolerated Dose
18%
Sorafenib
17%
pomalidomide
17%
Confidence Intervals
17%
Meta-Analysis
16%
Radiotherapy
15%
Data Analysis
15%
B-Cell Chronic Lymphocytic Leukemia
15%
Lenalidomide
14%
Quality of Life
14%
Consent Forms
14%
Precision Medicine
14%
Brachytherapy
14%
Patient Selection
13%
Platinum
13%
Bendamustine Hydrochloride
13%
Safety
13%
Guidelines
13%
Drug Development
12%
Sample Size
12%
Elderly
11%
Rituximab
11%
Population
11%
Random Allocation
11%
Paclitaxel
11%
Appointments and Schedules
11%
tanespimycin
11%
Mathematics
Toxicity
30%
Dose
25%
Dose Finding
22%
Design
20%
Oncology
18%
Cancer
14%
Efficacy
13%
Drugs
13%
Clinical Trials
11%
Regulator
7%
Phase I Trial
6%
Continual Reassessment Method
6%
Modular Design
5%
Biomarkers
5%
Treatment Effects
5%